ADC Therapeutics. (ADCT) is scheduled to host a conference call today at 8:00 a.m. EST to provide an update on its LOTIS-7 trial.
LOTIS-7 is a Phase 1b open-label clinical trial evaluating the safety and efficacy of the company's drug ZYNLONTA in combination with Roche's cancer med COLUMVI in patients with relapsed or refractory diffuse large B-cell lymphoma. A combination of ZYNLONTA plus polatuzumab vedotin and ZYNLONTA plus mosunetuzumab will also be evaluated in this trial.
According to the LOTIS-7 trial results presented at the European Hematology Association 2025 Congress this June, ZYNLONTA in combination with COLUMVI demonstrated an overall response rate of 93.3% and a complete response rate of 86.7% across 30 efficacy evaluable relapsed or refractory diffuse large B-cell lymphoma patients.
ADCT closed Tuesday's trading at $4.60, up 8.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.